HOME ·

Clinical Trial

KEYMED BIO-B (02162.HK): Global Phase III Trial of CMG901 (AZD0901) Meets Primary Endpoint, Delivers Improved OS for 2L+ Gastric Cancer; AstraZeneca Forecasts Peak Sales of USD3-5 Billion
Tags：
KEYMED BIO-B02162.HKAstraZenecaClinical Trial
2026-07-28
LEPU BIO (02157.HK): Global Phase III Trial of CMG901 Meets Primary Endpoint, Significantly Improves Overall Survival of CLDN18.2-positive Advanced Gastric Cancer Patients
Tags：
LEPU BIO02157.HKAstraZenecaClinical Trial
2026-07-28
INNOCARE (09969.HK): Phase III Trial of Fadeucravacitinib (ICP-488) for Moderate to Severe Plaque Psoriasis Meets Primary Endpoint
Tags：
INNOCARE09969.HKClinical Trialprimary endpoint
2026-07-27
SBP GROUP (01177.HK): IM-101 Injection (PreS1 Recombinant Fusion Protein) Obtains NMPA Clinical Trial Approval for Chronic Hepatitis B
Tags：
SBP GROUP01177.HKClinical Trial
2026-07-23
ORBUSNEICH (06929.HK): First Patient Enrolled in Pivotal Japanese Clinical Trial for Self-developed Drug-Coated Balloon
Tags：
ORBUSNEICH06929.HKClinical Trial
2026-07-22
JACOBIO-B (01167.HK): Pan-KRAS Inhibitor JAB-23E73 in Combination with Chemotherapy Completes First Patient Dosing in China for Phase Ib/III First-Line Treatment of KRAS-Mutant Pancreatic Cancer
Tags：
JACOBIO-B01167.HKClinical Trial
2026-07-20
INNOCARE (09969.HK): TYK2 Inhibitor Soficitinib (ICP-332) Meets Primary Endpoint in Phase II for Non-Segmental Vitiligo, 24-Week F-VASI Reduced by Around 39%-41% vs Baseline
Tags：
INNOCARE09969.HKClinical Trial
2026-07-16
HENLIUS (02696.HK): Biosimilar HLX18 to Nivolumab Doses First Patient in China for Global Multi-centre Phase I Trial
Tags：
HENLIUS02696.HKClinical Trial
2026-07-16
JENSCARE-B (09877.HK): LuX-Valve Plus Completes First Implantations in FDA US Pivotal Trial
Tags：
JENSCARE-B09877.HKClinical Trial
2026-07-16
ABBISKO-B (02256.HK): Oral Pan-KRAS Inhibitor ABSK211 Cleared by FDA for Phase I Trial in KRAS-Altered Solid Tumours
Tags：
ABBISKO-B02256.HKClinical Trial
2026-07-13
LONGBIO-B (01779.HK): Anti-IgE Antibody LP-003 Receives FDA Clinical Trial Clearance for Peanut Allergy
Tags：
LongBio-B01779.HKClinical Trial
2026-07-13
HENLIUS (02696.HK): NMPA Approves Phase I Trial for HLX37 (PD-L1/VEGF Bispecific) Plus Chemotherapy or HLX43 (PD-L1 ADC) in Solid Tumours
Tags：
HENLIUS02696.HKClinical Trial
2026-07-10
Shaanxi Micot Pharmaceutical Technology Co., Ltd (02335.HK): Phase II Clinical Study of Dual-Function Antithrombotic Candidate MT1002 for Anticoagulation in Haemodialysis Completes First Patient Enrolment
Tags：
Micot Pharma02335.HKClinical Trial
2026-07-09
HAIXI PHARMA(02637.HK): Phase III Clinical Trial of C019199 Tablets for Osteosarcoma Initiated
Tags：
HAIXI PHARMA02637.HKClinical Trial
2026-07-09
HENLIUS(02696.HK): First Patient Dosed in Phase I Clinical Trial of HLX05-N, a Cetuximab Biosimilar, for Metastatic Colorectal Cancer
Tags：
HENLIUS02696.HKClinical Trial
2026-07-08
INSILICO(03696.HK): Phase III Clinical Trial of Rentosertib for Idiopathic Pulmonary Fibrosis Officially Launched
Tags：
Insilico03696.HKClinical Trial
2026-07-08
Mabwell-B(02493.HK): IND Application of 9MW5211 Injection for Type 1 Diabetes Mellitus Accepted by NMPA
Tags：
MABWELL-B02493.HKClinical Trial
2026-07-07
CSPC PHARMA(01093.HK): Phase II Clinical Trial of SYH2070 Injection for Mixed Hyperlipidaemia Initiated at First Clinical Site in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-07-07
HENLIUS(02696.HK): Bispecific EGFR/c-MET ADC HLX48 Doses First Patient
Tags：
HENLIUS02696.HKClinical Trial
2026-06-30
REGENT PACIFIC(00575.HK): Deep Longevity Blood Biological Age Model Proven to Predict Mortality and Hospitalisation Risks in Research
Tags：
REGENT PACIFIC00575.HKClinical Trial
2026-06-30
Previous12 34